Are we reproducible in measurement of NET liver metastasis?

Détails

ID Serval
serval:BIB_B96B153BDFA9
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Are we reproducible in measurement of NET liver metastasis?
Périodique
Digestive and liver disease
Auteur⸱e⸱s
Moalla S., Arfi Rouche J., Foulon S., Caramella C., Ternes N., Planchard D., Goere D., Ducreux M., Scoazec J.Y., Deschamps F., Dromain C., Baudin E.
ISSN
1878-3562 (Electronic)
ISSN-L
1590-8658
Statut éditorial
Publié
Date de publication
10/2017
Peer-reviewed
Oui
Volume
49
Numéro
10
Pages
1121-1127
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Accurate measurement of well-differentiated neuroendocrine tumours (NET) liver metastases is critical to determine tumour slope and to assess treatment efficacy. Our objectives were to determine which CT or MRI sequence is the most reproducible to measure NET liver metastases and to assess the percentage of variability of measurements. Intra and inter-observer variability were studied on triphasic abdominal CT or liver MRI in 22 and 32 NET patients respectively. Patients were treatment-naïve or under somatostatin analogues. A maximum of 5 liver target lesions per patient was defined and three radiologists measured them on each sequence. Reproducibility were analysed by calculating the relative variation (RV) as defined by RECIST criteria. We analysed 1656 target measurements for CT and 3384 for MRI. Intra-observers RV were better than inter-observers. T2 for MRI and portal-phase for CT were associated with the lowest measurement variability. The MRI sequence offering the best intra and inter-observer reproducibility is the T2W-sequence. MRI allows more reproducible measurement than CT (inter-observer RV <20% in 96.8% for MRI and 81% for CT). Our study demonstrates intermediate to high imaging reproducibility of liver metastases measurements in NET patients. Non-enhanced MRI should be preferred to triphasic-CT for follow-up, assessment of treatment and trials.

Mots-clé
Metastasis, Neuroendocrine tumor, RECIST, Reproducibility
Pubmed
Création de la notice
07/09/2017 9:45
Dernière modification de la notice
20/08/2019 15:27
Données d'usage